drugset / Trial / NCT04105959

A Study to Investigate the Effects of RIST4721 on the Inflammatory Response in Healthy Male Subjects Using a Blister Model

NCT04105959

Phase 1 Completed 32 enrolled Aristea Therapeutics, Inc.
RandomizedCrossoverSingle-blindTreatment

Summary

A Randomised, Single-Blind, Placebo-Controlled, Crossover Study to Investigate the Effects of RIST4721, a Novel CXCR2 Inhibitor, on the Inflammatory Response in Healthy Male Subjects Using a Standardized Blister Model

Timeline

Start
2019-07-25
Primary completion
2019-11-19
Completion
2019-12-09

Drugs

EvaluationDrugModalityDoseRoute
Subject VIMNERIXIN Small molecule 150 mg Oral
Subject VIMNERIXIN Small molecule 300 mg Oral

Indications